I think the way the game is played has changed dramatically. The FDA process has changed. The way investors see biotech has changed. The money supply has dried up. I don't see any way for any management to have foreseen these new conditions. Hindsight is always 20/20.
The quick shift to RD is the only reason we're all still here with something important to talk about. In short, management played the hand dealt to them. Yes, it's the eleventh hour, but we're still in the game.